Clinical Trials Directory

Trials / Completed

CompletedNCT01932060

Oxytocin Infusions and Blood Loss in Patients Undergoing Elective Cesarean Delivery.

Effects of Different Oxytocin Infusions on Blood Loss and Postpartum Hemoglobin Values in Patients Undergoing Elective Cesarean Delivery

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
51 (actual)
Sponsor
Stanford University · Academic / Other
Sex
Female
Age
18 Years – 40 Years
Healthy volunteers
Accepted

Summary

Although prior dose-finding studies have investigated the optimal bolus dose of oxytocin to initiate adequate uterine tone, it is unclear what oxytocin infusion regimen is required to maintain adequate uterine tone after delivery. The study investigators aim to compare two different infusion rates of oxytocin to assess the optimal infusion regimen for reducing blood loss in women undergoing elective Cesarean delivery.

Detailed description

Oxytocin (pitocin) is a drug commonly used in obstetric practice, and the drug effect is to increase the muscular tone of the uterus to reduce uterine bleeding after neonatal delivery. Pregnant patients undergoing elective (scheduled)Cesarean delivery routinely receive oxytocin after delivery of the baby. Post-delivery, oxytocin is commonly administered as an IV bolus and/or infusion. No previous studies have accurately assessed differences in oxytocin infusions after delivery in patients undergoing elective cesarean delivery. Thus the study aim is to investigate which infusion rate can optimally provide adequate maintenance of uterine tone during Cesarean delivery while being associated with minimal or no maternal side-effects.

Conditions

Interventions

TypeNameDescription
DRUGOxytocin InfusionPatient will receive a blinded infusion of oxytocin after the time of delivery of the fetus which will terminate at the time of discharge from the post-anesthesia care unit.

Timeline

Start date
2013-08-01
Primary completion
2015-09-01
Completion
2015-09-01
First posted
2013-08-30
Last updated
2017-02-01
Results posted
2017-02-01

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01932060. Inclusion in this directory is not an endorsement.